GSK3128349

GSK3128349 is a radiolabeled albumin-binding domain antibody (AlbudAb), classified as a biopharmaceutical and developed as a diagnostic imaging agent. Its mechanism of action is **binding to serum albumin with high affinity**, allowing it to serve as a molecular tracer for positron emission tomography (PET) imaging of albumin biodistribution and pharmacokinetics in humans. GSK3128349 itself has no intrinsic pharmacological activity. It can be used as a carrier or label to study plasma and tissue pharmacokinetics for attached therapeutic payloads or as a tool in drug development and imaging. The radiolabeled version (89Zr-GSK3128349) has been investigated in first-in-human studies for biodistribution, tissue penetration, and clearance profiles via PET/CT imaging in healthy volunteers. Developed by GSK, the AlbudAb platform exploits the long circulatory half-life of albumin, and GSK3128349 binds human albumin with subnanomolar affinity (Kd ≈ 0.85 nM)[2][3][1].

Other names

89Zr-labeled albumin-binding domain antibody89Zr-AlbudAb